The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity
Status:
NOT_YET_RECRUITING
Trial end date:
2030-12-01
Target enrollment:
Participant gender:
Summary
The goal of the PARTUM trial is to determine if taking low-dose aspirin daily for 6 weeks after delivery is similar (non-inferior) to usual care low-molecular-weight heparin injections to prevent venous thromboembolism (VTE: blood clots in the legs or lungs) for postpartum individuals with VTE risk factors.